Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin plus N-acetylcysteine versus rifaximin alone for IBS-D
IRCT20141201020178N13Phase 3Recruiting
- Sponsor
- Iran University of Medical Sciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rifaximin and acetylcysteine in Diarrhea-predominant irritable bowel syndrome (IBS-D) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoint: Efficacy on symptoms and quality of life. Started Oct 2026; status: recruiting.
02
Drugs
rifaximinacetylcysteine
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on IRCT20141201020178N13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141201020178N13.